Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.88
−$0.02 · -1.05%
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Latest quote
$1.88
−$0.02 · -1.05%
Regular session · ET · Market data may be delayed.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Regular session · ET · Market data may be delayed.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | 1.26M USD | 2.1M USD | 5.53M USD |
| Selling, general, and administrative | 2.51M USD | 1.92M USD | 3.1M USD |
| Operating expenses | 3.77M USD | 4.03M USD | 8.64M USD |
| Interest income | 25.61K USD | 142.6K USD | 360.12K USD |
| Interest expense | 100.88K USD | 5K USD | 10K USD |
| Depreciation and amortization | 119.98K USD | 118.59K USD | 120.99K USD |
| Operating income | −3.77M USD | −4.03M USD | −8.64M USD |
| Net income | −3.85M USD | −4.86M USD | −8.28M USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 22, 2026 | 1:10 | — | — |
Effective Jun 22, 2026
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
